Serial No. 09/966,493

Claim 1 (currently amended): A swallowable immediate release tablet comprising at least 60 weight % of acetaminophenan active ingredient and a powdered wax having an melting point greater than about 90° C and a particle size in the range of about 5 to about 100 microns, wherein the acetaminophen is released from the swallowable immediate release tablet by 30 minutes in pH 5.8 buffer said swallowable immediate release tablet meeting the USP dissolution specifications for immediate release tablets containing said active ingredient.

Claim 2 (cancelled)

Claim 3 (previously presented): The tablet of claim 1, wherein the wax is selected from the group consisting of linear hydrocarbons, microcrystalline wax, and mixtures thereof.

Claim 4 (previously presented): The tablet of claim 1 prepared by direct compression.

Claim 5 (previously presented): The tablet of claim 1 which is substantially free of water-soluble, non-saccharide polymeric binders.

Claim 6 (previously presented): The tablet of claim 1, which is substantially free of hydrated polymers.

Claim 7 (previously presented): The tablet of claim 1 further comprising at least one outer coating.

Claim 8 (previously presented): The tablet of claim 7, wherein the outer coating comprises a material selected from the group consisting of gelatin, isomalt, monosaccharides, disaccharides, polysaccharides such as starch, cellulose derivatives, shellacs, polyhedric alcohols such as xylitol, mannitol, sorbitol, maltitol, erythritol, and polyalkylene glycols.

6223-1 3

Serial No. 09/966,493

Claim 9 (previously presented):

The tablet of claim 1 comprising up to about 20

weight percent wax.

Claim 10 (previously presented): The tablet of claim 1 further comprising an

excipient selected from the group consisting of disintegrants, flow aids, and optionally

lubricants.

Claim 11 (previously presented): The tablet of claim 1 further comprising an insert

disposed within tablet.

Claim 12 (previously presented): The tablet of claim 11, wherein the insert comprises

additional active ingredient.

Claim 13 (previously presented): The tablet of claim 12, wherein the additional active

ingredient has a different release profile from the active ingredient in the tablet.

Claim 14 (previously presented): The tablet of claim 12, wherein the amount of

additional active ingredient is from about 0.1 to about 30 mg.

Claim 15 (previously presented): The tablet of claim 12, wherein the additional active

ingredient is selected from the group consisting of loratadine, fexofenadine, cetirizine,

chlorpheniramine, brompheniramine, diphenhydramine, pseudoephedrine,

cyproheptadine, montelukast, loperamide, famotidine, dexamethasone, hydrocortisone,

cyclobenzaprine, alendronate, hydrochlorthiazide, rofecoxib, indomethacin, ketoprofen, meloxicam, piroxicam, lovastatin, atorvastatin, pravastatin, simvastatin, finasteride, and

pharmaceutically acceptable salts, esters, and mixtures thereof.

Claim 16 (cancelled)

6223-1 4

Serial No. 09/966,493

Claim 17 (currently amended): A swallowable immediate release tablet comprising at least 60 weight percent of acctaminophenan active ingredient and a powdered wax having a particle size is in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof; wherein said swallowable immediate release tablet is prepared by direct compression, and the acctaminophen is released from the swallowable immediate release tablet by 30 minutes in pH 5.8 buffer.

Claim 18 (currently amended): A swallowable_immediate release tablet comprising at least 60 weight percent of acctaminophenan active ingredient and a powdered wax having a particle size in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof; wherein said swallowable immediate release tablet is substantially free of water-soluble, non-saccharide polymeric binders, and the acctaminophen is released from the swallowable immediate release tablet by 30 minutes in pH 5.8 buffer.

Claim 19 (currently amended): A swallowable immediate release tablet comprising at least 60 weight percent of acctaminophenan active ingredient and a powdered wax having a particle size is in the range of about 5 to about 100 microns that is selected from the group consisting of shellac wax, paraffin-type waxes, polyethylene glycol, and mixtures thereof; wherein said swallowable immediate release tablet is substantially free of hydrated polymers, and the acetaminophen is released from the swallowable immediate release tablet by 30 minutes in pH 5.8 buffer.

Claim 20 (cancelled):

6223-1 5